10 news items
Alnylam Issues 2023 Corporate Responsibility Report
ALNY
7 May 24
and engage with us on X (formerly Twitter
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
and engage
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
and engage
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
ALNY
20 Mar 24
and engage
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
ALNY
13 Mar 24
and on their entire family," said Tiffany Patrick, MPH, MBA, Vice President, Patient Advocacy and Engagement at Alnylam Pharmaceuticals
ogtp893z3yim9e4tumur65upapc536kangkjepvf3df9bby8joqqf
ALNY
11 Mar 24
officers and/or directors have engaged in securities fraud or other unlawful business practices
dyqbd002yi
ALNY
7 Mar 24
concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices
4itusuwp6pifbbs8ch8alaxze9xcz5jijbjtbno ns2eyd8n8q15erxlaj
ALNY
5 Mar 24
and engage with us on X (formerly Twitter
0cyro 4a671c8cya5nrjs28zbiuogqkdzx8xm321i5gom2umtmov3
ALNY
3 Mar 24
officers and/or directors have engaged in securities fraud or other unlawful business practices
rxtsefqlfo8nwq4hnt9tjl7xrubyqqivkwh7p5r62bzfwrvungcs1y5tdbb
ALNY
28 Feb 24
concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices
- Prev
- 1
- Next